Skip to content
Screener

Net Change in Cash at other companies

Pfizer logo
PfizerPFE
$563M+50.1%
Amgen logo
AmgenAMGN
$1.95B+349%
Incyte logo
IncyteINCY
$521.24M+3,782%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$45.12M+507%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$120.57M+492%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$51M-191%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$7.14B+366%
Enterprise value$6.92B+372%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:21 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-205170
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of common stock upon stock option exercises5,756136
Proceeds from issuance of common stock from Employee Stock Purchase Plan1,062584
Net cash provided by financing activities52,53624,970
Net (decrease) increase in cash, cash equivalents and restricted cash(70,804)27,838
Cash, cash equivalents and restricted cash at beginning of period312,42898,165
Cash, cash equivalents and restricted cash at end of period$241,624$126,003
Supplemental disclosure of noncash investing and financing information:
Property & equipment included in accounts payable and accrued expenses$152$79

Item 1. Financial Statements (Unaudited)

FAQ

What is Cogent Biosciences, Inc.'s net change in cash?
Cogent Biosciences, Inc. (COGT) reported net change in cash of -$70.8M in Q1 2026.
How has Cogent Biosciences, Inc.'s net change in cash changed year-over-year?
Cogent Biosciences, Inc.'s net change in cash decreased by 354.3% year-over-year, from $27.84M to -$70.8M.
What is the long-term trend for Cogent Biosciences, Inc.'s net change in cash?
Over 2 years (2022 to 2025), Cogent Biosciences, Inc.'s net change in cash has grown at a 64.6% compound annual growth rate (CAGR), from -$79.8M to $216.23M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Cogent Biosciences, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude